

WHAT IS CLAIMED IS:

1. An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC and LC immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn; and, wherein the antibody comprises:

(i) a HC that comprises a HC CDR1 comprising an amino acid sequence RSWMN (SEQ ID NO: 11), a HC CDR2 comprising an amino acid sequence RIHPGDGDTNYNGKFKG (SEQ ID NO: 12), and a HC CDR3 comprising an amino acid sequence EGSPYFDY (SEQ ID NO: 13); and a LC that comprises a LC CDR1 comprising an amino acid sequence SASSSISSNYLH (SEQ ID NO: 8), a LC CDR2 comprising an amino acid sequence RTSNLAS (SEQ ID NO: 9), and a LC CDR3 comprising an amino acid sequence QQGSNIPLT (SEQ ID NO: 10); or

(ii) a HC that comprises a HC CDR1 comprising an amino acid sequence DYAMH (SEQ ID NO: 17), a HC CDR2 comprising an amino acid sequence VITNYYGDASYNQKFKG (SEQ ID NO: 18), and a HC CDR3 comprising an amino acid sequence GGYDGYVDFDY (SEQ ID NO: 19); and a LC that comprises a LC CDR1 comprising an amino acid sequence KASQDINNYIA (SEQ ID NO: 14), a LC CDR2 comprising an amino acid sequence YTSTLQP (SEQ ID NO: 15), and a LC CDR3 comprising an amino acid sequence LQYDNLLRT (SEQ ID NO: 16).

2. The isolated antibody of claim 1, wherein the HC comprises:

a HC CDR1 comprising the amino acid sequence RSWMN (SEQ ID NO: 11), a HC CDR2 comprising the amino acid sequence RIHPGDGDTNYNGKFKG (SEQ ID NO: 12), and a HC CDR3 comprising the amino acid sequence EGSPYFDY (SEQ ID NO: 13) and

the LC comprises:

a LC CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 8),

a LC CDR2 comprising the amino acid sequence RTSNLAS (SEQ ID NO: 9), and

a LC CDR3 comprising the amino acid sequence QQGSNIPLT (SEQ ID NO: 10).

3. The isolated antibody of claim 1, wherein the HC comprises:
a HC CDR1 comprising the amino acid sequence DYAMH (SEQ ID NO: 17), a HC CDR2 comprising the amino acid sequence VITNYYGDASYNQKFKG (SEQ ID NO: 18), and a HC CDR3 comprising the amino acid sequence GGYDGYVDFDY (SEQ ID NO: 19) and the LC comprises:
a LC CDR1 comprising the amino acid sequence KASQDINNYIA (SEQ ID NO: 14), a LC CDR2 comprising the amino acid sequence YTSTLQP (SEQ ID NO: 15), and a LC CDR3 comprising the amino acid sequence LQYDNLLRT (SEQ ID NO: 16).
4. The isolated antibody of claim 1, wherein (i) the LC immunoglobulin variable domain sequence of the isolated antibody comprises an amino acid sequence of SEQ ID NO: 20, and the HC immunoglobulin variable domain sequence of the isolated antibody comprises an amino acid sequence of SEQ ID NO: 21; or (ii) wherein the LC immunoglobulin variable domain sequence of the isolated antibody comprises an amino acid sequence of SEQ ID NO: 22, and the HC immunoglobulin variable domain sequence of the isolated antibody comprises an amino acid sequence of SEQ ID NO: 23.
5. An isolated antibody, wherein the antibody binds to an FcRn epitope comprising an amino acid sequence selected from the group consisting of CSAFSFYPPQLRFLRNGL (SEQ ID NO: 26), and APGTPAFWVSGWLGPQQYLS (SEQ ID NO: 27).
6. The isolated antibody of any one of claims 1-5, for use as a medicament for modulating an FcRn activity in a human subject.
7. The antibody of any one of claims 1-6 for use in treating an autoimmune disorder and/or modulating symptoms of an autoimmune disorder.
8. The antibody of claim 7, wherein the autoimmune disorder is a disorder selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Myasthenia Gravis (MG), Graves Disease, Idiopathic Thrombocytopenia Purpura (ITP), Guillain-Barre Syndrome, autoimmune myocarditis, Membrane Glomerulonephritis, diabetes mellitus, Type I or Type II diabetes, multiple